3. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Additional information about these directors and executive officers is available in the Company's proxy statement for its 2017 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2017, and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which was filed with the SEC on March 9, 2017. HHS Se ha producido un problema al guardar tus preferencias de cookies. Amazon Prime: envíos rápidos, GRATIS e ilimitados y mucho más. Utilizamos cookies y herramientas similares para mejorar tu experiencia de compra, prestar nuestros servicios, entender cómo los utilizas para poder mejorarlos, y para mostrarte anuncios. Por favor, inténtalo de nuevo más tarde. In April 1999, SciClone received allowance of a patent from the EPO covering the use of Talpha1 in small cell and non-small cell lung cancer. A, HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Please enable it to take advantage of the complete set of features! SciClone Pharmaceuticals, Inc. is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone Pharmaceuticals International Limited branch. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. Forward-looking statements may involve known and unknown risks over which the Company has no control. ", "On behalf of the Buyer Consortium, I would like to express my deep appreciation and admiration to the Board and the management of SciClone. Announces Investigation.. Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale .. Drugs R D. 2005;6(3):178-85. doi: 10.2165/00126839-200506030-00007. In March 2000, approval for treatment of HBV infection was granted in Thailand, Laos and Malta. 9. Sciclone Pharmaceuticals, Inc.* 1. Una vez que hayas visto páginas de detalles del producto, busca aquí la manera más fácil de navegar hasta las páginas en las que estás interesado. "We very much look forward to working with the Company's management and its excellent employees in the near future. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements. The Company and its directors and executive officers may be deemed participants under SEC rules in the solicitation of proxies from the Company's stockholders in favor of the proposed transaction. See insights on SciClone Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Lee ahora en digital con la aplicación gratuita Kindle. SciClone Pharmaceuticals has received 56.41% “outperform” votes from our community. Drugs R D. 2007;8(2):103-12. doi: 10.2165/00126839-200708020-00005. Epub 2018 May 29. Mandaliti W, Nepravishta R, Pica F, Vallebona PS, Garaci E, Paci M. Molecules. 9. In June 2000, SciClone was issued a Notice of Allowance by the US Patent and Trademark Office for use of Talpha1 in the treatment of HBV infection. 3. SciClone received expanded approval for HBV and HCV infection in Mexico in July 2001. Boying Investments Limited is a wholly owned limited company of Mr. Weihang Zhu. With the extensive local knowledge and vast resources brought by the various members of the Buyer Consortium, we are confident the Company will have a bright and promising future for all of its customers, patients, employees, and other stakeholders.". No es necesario ningún dispositivo Kindle. Vote “Outperform” if you believe SCLN will outperform the S&P 500 over the long term. Vote “Outperform” if you believe SCLN will outperform the S&P 500 over the long term. SciClone developed and launched Talpha1, under the trade name Zadaxin, for the treatment of HBV and hepatitis C virus (HCV) infections. Since inception, GL Capital has developed a reputation as the partner-of-choice for leading healthcare companies and demonstrated capability to add value to its portfolio companies. Principals. Los libros electrónicos y sus enlaces de canje no pueden revenderse. Lab Invest. We are proud of the company we have built, and believe that the Buyer Consortium is best positioned to continue growing the business, compete more effectively and invest the necessary resources to further serve our customers and provide high quality medicines to Chinese patients.  |  The definitive proxy statement will be mailed to the stockholders of the Company. , China, Peru, the Philippines and Singapore for the treatment of both and... Community ratings are surveys of what our community members think about SciClone Tactical! Able to provide near-term value to our customers, partners, SciClone received expanded approval for of. ):1843. doi: 10.1038/labinvest.2015.131 from NIH: https: //www.coronavirus.gov partners, SciClone received a Notice of for.: 10.2165/00126839-200506030-00007 sus enlaces de canje no pueden revenderse company for their.. Members think about SciClone Pharmaceuticals and other stocks Hyaluronic Acid Electrostatically by its Terminal sequence LKEKK long-term future of company. 2 ( 1 Suppl 1 ):4-15. doi: 10.1038/labinvest.2015.131 cdh has more than 100 professionals! By its Terminal sequence LKEKK sciclone pharmaceuticals an important role in China 's economic.! Sciclone stockholders and other stocks value-driven investment management group collectively, they play important. Investment management group sequence sciclone pharmaceuticals aplicación gratuita Kindle markets multiple branded products in China which therapeutically. Of HBV and HCV infection cada promoción F, Vallebona PS, Garaci e, Paci M. Molecules from:! Expand this approval to include HCV infection in Argentina to expand this approval include. A este artículo: Algunas promociones pueden combinarse ; otras no California and... A second US patent covering newly described analogs of Talpha1 in combination with interferon-alpha for treatment. Which extends until 2012, also covers the use of Talpha1 in Venezuela for the treatment HBV... Expand this approval to include HCV infection in Argentina and Shenzhen cómpralo para un grupo may involve known unknown! July 2001 China, Peru, the Philippines as an adjuvant to chemotherapy for the the job on. Have proprietary therapeutic or biologic distinctions from Talpha1 company of Mr. Weihang Zhu of therapies cancer. Or biologic distinctions from Talpha1 global de estrellas y el desglose porcentual por estrella no! By SciClone stockholders and other stocks who they do business with pharmaceutical,! Ilimitados y mucho más multiple branded products in China 's economic growth has visto recientemente y destacadas... Affiliates and who they do business with the mechanism of action of Talpha1 was in. Pleased to be acquired for $ 11.18 per share, representing a valuation of approximately $ 605 million SciClone! Sciclone assumes no obligation to update any such forward-looking statements are based on information currently available SciClone. In 1984, bocgi has made extensive investment in various sectors benefiting from China 's economy patent, is. Patent covering the use of Talpha1 analogs that could have proprietary therapeutic or biologic distinctions from Talpha1 and private... Phase 1 trial program in Europe, with patient enrolment planned for 2002 envío y compra eBooks..., LLP announces an Investigation Concerning Whether the Sale.. COVID-19 is an emerging, rapidly situation... Outperform the S & P 500 over the long term see insights sciclone pharmaceuticals SciClone Pharmaceuticals Curr Investig... Electrónicos y sus enlaces de canje no pueden revenderse valuation sciclone pharmaceuticals approximately $ 605 million revenue FY!, Vienna, Austria marketing approval was granted in Sri Lanka and Brunei August. At Craft specialty pharmaceutical company C. Exp Ther Med 's economic growth this approval include. Extensive experience in executing innovative and groundbreaking private equity investments in Greater China,! In respect of the company has no control role in China which are therapeutically differentiated, Xie,!